RxDoctor Payments DataLook up a doctor →

Sandeep Amin, MD

Interventional Pain Medicine · Chicago, ILNPI 1184792251

Payments from drug & device makers

$429,773in general payments, 2019–2025

Across 678 payments — averaging $633.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanos Medical$262K
  • Abbott$72K
  • Nevro Corp.$41K
  • Boston Scientific$31K
  • Medtronic$13K
  • Spinal Simplicity, LLC$9K
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$58,44514%
  • Speaking & faculty fees$311,23572%
  • Travel & lodging$37,9829%
  • Food & beverage$18,5044%
  • Education$3,5001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$429,773 in reported general payments places this provider in the 95th percentile of 93 interventional pain medicine providers in Illinois.

See all interventional pain medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$266,920
Medicare patients
495
Services billed
5,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl21$22,050
OxycontinOxycodone Hcl18$16,233
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen379$13,116
MovantikNaloxegol Oxalate32$12,575
Buprenorphine44$10,611
Lidocaine40$4,298
Gabapentin240$3,428
Morphine Sulfate ErMorphine Sulfate76$3,049
Pregabalin152$2,661
Tizanidine Hcl210$2,435
Celecoxib45$2,041
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen49$2,002
Fentanyl25$1,934
Oxycodone Hcl76$1,665
Cyclobenzaprine Hcl99$1,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$63$22,05021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 interventional pain medicine providers in Illinois.

Other interventional pain medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →